About Redpin Therapeutics
Redpin Therapeutics is a company based in New York (United States) founded in 2017 was acquired by Kriya Therapeutics in November 2022.. Redpin Therapeutics has raised $17 million across 2 funding rounds from investors including ARE, Takeda Pharmaceuticals and Kriya Therapeutics. Redpin Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17 M (USD)
in 2 rounds
-
Latest Funding Round
$15.5 M (USD), Series A
Mar 09, 2020
-
Investors
ARE
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Kriya Therapeutics
(Nov 16, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Redpin Therapeutics
Redpin Therapeutics has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $15.5 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $15.5M
-
First Round
First Round
(29 Mar 2018)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Series A - Redpin Therapeutics | Valuation | 4Bio Capital , Arkin Holdings | |
| Mar, 2018 | Amount | Seed - Redpin Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Redpin Therapeutics
Redpin Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Takeda Pharmaceuticals and Kriya Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Redpin Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Redpin Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Redpin Therapeutics Comparisons
Competitors of Redpin Therapeutics
Redpin Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Redpin Therapeutics
Frequently Asked Questions about Redpin Therapeutics
When was Redpin Therapeutics founded?
Redpin Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Redpin Therapeutics located?
Redpin Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Redpin Therapeutics a funded company?
Redpin Therapeutics is a funded company, having raised a total of $17M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Mar 29, 2018.
What does Redpin Therapeutics do?
Developer of cell therapies for Neurological and Psychiatric disorders. The company has developed a proprietary chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline. The platform is leveraging ion channels as neuromodulation tools to either stimulate under-active neurons or inhibit over-active ones. The company has engineered the ion channel gene into a viral vector (adeno-associated virus, or AAV) and administered it to the patient.
Who are the top competitors of Redpin Therapeutics?
Redpin Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Redpin Therapeutics's investors?
Redpin Therapeutics has 6 investors. Key investors include ARE, Takeda Pharmaceuticals, Kriya Therapeutics, 4Bio Capital, and Arkin Holdings.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.